SELLAS Life Sciences Reports Positive WT1 Cancer Vaccine Clinical Results in Mesothelioma and Acute Myeloid Leukemia (AML) Patients SELLAS Life Sciences Group announced that positive data from the company’s clinical studies of its WT1 cancer vaccine in patients with malignant pleural mesothelioma and AML were reported. [Press release from SELLAS Life Sciences Group discussing research presented at the International WT1 Conference, Kyoto] Press Release Bristol-Myers Squibb to Present New Data across Multiple Blood Cancers Bristol-Myers Squibb will present data for elotuzumab in patients with relapsed or refractory (R/R) multiple myeloma; for Opdivo for investigational use in patients with R/R classical Hodgkin lymphoma; and for Sprycel in chronic myeloid leukemia. [Press release from Bristol-Myers Squibb Company discussing research to be presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release City of Hope Researchers Present Study Results Among the research presented by City of Hope scientists will be results of three Phase I clinical trials that lay the groundwork for novel leukemia or lymphoma treatments. [Press release from City of Hope discussing research to be presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release Novartis Announces New CTL019 Study Data Demonstrating Overall Response in Adult Patients with Certain Types of Lymphoma Findings from an ongoing Phase IIa study to evaluate the safety and efficacy of investigational chimeric antigen receptor T cell therapy CTL019 in certain types of relapsed or refractory non-Hodgkin lymphoma were presented. [Press release from Novartis AG discussing research presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release Amgen Presents Data from Three Trials Evaluating BLINCYTO® (Blinatumomab) In Acute Lymphoblastic Leukemia Amgen announced that new data from three Phase II trials support the efficacy and safety of BLINCYTO® in adults with acute lymphoblastic leukemia. [Press release from Amgen, Inc. discussing research presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release Gene Therapy Restores Immunity in Children and Young Adults with Rare Immunodeficiency Gene therapy can safely rebuild the immune systems of older children and young adults with X-linked severe combined immunodeficiency, a rare inherited disorder that primarily affects males, scientists have found. [Press release from National Institute of Allergy and Infectious Diseases discussing research presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release Juno’s Investigational CAR T Cell Product Candidates JCAR014 and JCAR018 Demonstrate Encouraging Clinical Responses in Patients with B-Cell Cancers Juno Therapeutics, Inc. announced, in partnership with its collaborators, that clinical data from a chimeric antigen receptor (CAR) T cell product candidate, JCAR014, demonstrated encouraging clinical responses in patients with relapsed or refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. [Press release from Juno Therapeutics, Inc. discussing research presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release IMiD® Combination Therapies Form Backbone of Multiple Myeloma Research Celgene Corporation announced that nearly 30 combination studies including IMiD® compounds, REVLIMID® and POMALYST®/IMNOVID®, across a range of patient segments within multiple myeloma are being presented. [Press release from Celgene Corporation discussing research presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release bluebird bio Presents Pre-Clinical and Manufacturing Data from CAR T Oncology Programs bluebird bio, Inc., a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that pre-clinical data from its anti-B cell maturation antigen oncology program were presented. [Press release from bluebird bio, Inc. discussing research presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release From our sponsor: Free wallchart from Nature Neuroscience – Neural Stem Cells. Request your copy. |